

Fiscal Year 2010 Annual Review of Xopenex® (levalbuterol) Nebulizer Solution

Prior Authorization Criteria

Prior authorization is not required for a total duration of 90 days per every 365 days. Use of this product in excess of 90 days of therapy in a 360 day period will require a prior authorization that includes:

- In the prior authorization request, the prescriber should document why the member is unable to use racemic albuterol. For those members with asthma, members should also be utilizing inhaled corticosteroid (ICS) therapy for long-term control per NAEPP guidelines.
- Clinical exceptions will be made for members with COPD.
- Quantity Limit of 288mls per 30 days will also apply.

Utilization of Xopenex® Nebulizer Solution

Utilization Trends


Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2009	8,656	14,649	\$2,692,142.77	\$183.78	\$10.47	2,136,867	257,116
2010	7,261	12,208	\$2,203,429.59	\$180.49	\$10.18	1,677,075	216,549
Percent Change	-16.10%	-16.70%	-18.20%	-1.80%	-2.80%	-21.50%	-15.80%
Change	-1,395	-2,441	-\$488,713.18	-\$3.29	-\$0.29	-459,792	-40,567

Utilization Details FY 2010


Brand Name	Claims	Members	Days	Cost	Perdiem	Claims/Member	% Cost
XOPENEX NEB 0.63MG	5,866	3,625	104,828	\$1,068,848.35	\$10.20	1.62	48.51%
XOPENEX NEB 1.25/3ML	3,201	1,841	58,403	\$604,710.12	\$10.35	1.74	27.44%
XOPENEX NEB 0.31MG	3,100	2,121	52,679	\$522,496.14	\$9.92	1.46	23.71%
LEVALBUTEROL NEB 1.25/0.5	31	24	444	\$5,846.09	\$13.17	1.29	0.27%
XOPENEX CONC NEB 1.25/0.5	10	7	195	\$1,528.89	\$7.84	1.43	0.07%
Total	12,208	7,261*	216,549	\$2,203,429.59	\$10.18	1.68	100.00%

*Unduplicated total number of members.

Demographics of Members Utilizing Xopenex® Nebulizer Solution for FY 2010




Prescriber Specialty by Number of Claims for FY 2010



Prior Authorization of Xopenex® Nebulizer Solution

There were a total of 769 petitions submitted for this PBPA category during Fiscal Year 2010. The following chart shows the status of the submitted petitions.

Status of Petitions for Osteoporosis Medications: FY 2010



Market News and Update

The first patents for Xopenex® expired in January 2010. However, due to manufacturer negotiations, the only Xopenex® product available in generic formulation is the concentrated Xopenex® 1.25mg/0.5mL, which must be diluted before use and is minimally utilized compared with the other products. The next Xopenex® patent is set to expire in March 2013.

Conclusions

The College of Pharmacy recommends no changes to this category at this time.